RxDoctor Payments Data

Catherine Vanpoznak, MD

Medical Oncology · Ann Arbor, MINPI 1225109242

Payments from drug & device makers

What this record shows

This record is dominated by education: $80 of the $80 with a category attached, or 100.0%. AstraZeneca accounts for 85.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in MI, where the typical reported total is $1,832.

$80in general payments, 2019–2025

Across 2 payments — averaging $40.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$68
  • Gilead$12
$231,317in research payments, 2019–2025

Across 7 payments — averaging $33,045 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$207K
  • Genentech, Inc.$24K

What the payments were for

  • Education$80100%

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$68
Gilead1$12

How this compares

$80 in reported general payments places this provider in the 20th percentile of 170 medical oncology providers in Michigan.

See all medical oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$25,665
Medicare patients
88
Services billed
255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib35$559,304
Anastrozole273$12,458
Exemestane39$11,024
Letrozole28$2,508
Tamoxifen Citrate43$1,354
Alendronate Sodium21$391

Paid to pharmacies, not to this prescriber.

Other medical oncology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →